Zhu Chuan-Jiang, Hua Fang, Zhu Xiao-Lu, Li Meng, Wang Hong-Xu, Yu Xiao-Ming, Li Yan
Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Beijing, China; Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Beijing, China.
Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
PLoS One. 2015 Aug 21;10(8):e0135866. doi: 10.1371/journal.pone.0135866. eCollection 2015.
The (-)- and (+)-clausenamide (CLA) enantiomers have different pharmacokinetic effects in animals, but their association with putative stereoselective regulation of P-glycoprotein (P-gp) remains unclear. Using three cells expressing P-gp-Caco-2, KBv and rat brain microvessel endothelial cells(RBMEC), this study investigated the association of CLA enantiomers with P-gp. The results showed that the rhodamine 123 (Rh123) accumulation, an indicator of P-gp activity, in Caco-2, KBv and RBMECs was increased by (-)CLA (1 or 5 μmol/L) at 8.2%-28.5%, but reduced by (+)CLA at 11.7%-25.9%, showing stereoselectivity in their regulation of P-gp activity. Following co-treatment of these cells with each CLA enantiomer and verapamil as a P-gp inhibitor, the (+)-isomer clearly antagonized the inhibitory effects of verapamil on P-gp efflux, whereas the (-)-isomer had slightly synergistic or additive effects. When higher concentrations (5 or 10 μmol/L) of CLA enantiomers were added, the stimulatory effects of the (+)-isomer were converted into inhibitory ones, leading to an enhanced intracellular uptake of Rh123 by 24.5%-58.2%; but (-)-isomer kept its inhibition to P-gp activity, causing 30.0%-63.0% increase in the Rh123 uptake. The biphasic effects of (+)CLA were confirmed by CLA uptake in the Caco-2 cells. (+)CLA at 1 μmol/L had significantly lower intracellular uptake than (-)CLA with a ratio[(-)/(+)] of 2.593, which was decreased to 2.167 and 1.893 after CLA concentrations increased to 2.5 and 5 μmol/L. Besides, in the non-induced KB cells, (+)CLA(5 μmol/L) upregulated P-gp expression at 54.5% relative to vehicle control, and decreased Rh123 accumulation by 28.2%, while (-)CLA(5 μmol/L) downregulated P-gp expression at 15.9% and increased Rh123 accumulation by 18.0%. These results suggested that (-)CLA could be a P-gp inhibitor and (+)CLA could be a modulator with concentration-dependent biphasic effects on P-gp activity, which may result in drug-drug interactions when combined with other P-gp substrate drugs.
(-)-和(+)-黄皮酰胺(CLA)对映体在动物体内具有不同的药代动力学效应,但其与P-糖蛋白(P-gp)假定的立体选择性调节之间的关联仍不清楚。本研究使用三种表达P-gp的细胞——人结肠腺癌上皮细胞(Caco-2)、长春新碱耐药细胞(KBv)和大鼠脑微血管内皮细胞(RBMEC),研究CLA对映体与P-gp的关联。结果显示,作为P-gp活性指标的罗丹明123(Rh123)在Caco-2、KBv和RBMEC细胞中的蓄积,在加入(-)CLA(1或5 μmol/L)后增加了8.2%-28.5%,但在加入(+)CLA后减少了11.7%-25.9%,表明它们对P-gp活性的调节具有立体选择性。在用每种CLA对映体与维拉帕米(一种P-gp抑制剂)共同处理这些细胞后,(+)-异构体明显拮抗维拉帕米对P-gp外排的抑制作用,而(-)-异构体具有轻微的协同或相加作用。当加入更高浓度(5或10 μmol/L)的CLA对映体时,(+)-异构体的刺激作用转变为抑制作用,导致Rh123的细胞内摄取增加24.5%-58.2%;但(-)-异构体保持其对P-gp活性的抑制作用,使Rh123摄取增加30.0%-63.0%。Caco-2细胞对CLA的摄取证实了(+)CLA的双相效应。1 μmol/L的(+)CLA的细胞内摄取显著低于(-)CLA,其[(-)/(+)]比值为2.593,当CLA浓度增加到2.5和5 μmol/L后,该比值分别降至2.167和1.893。此外,在未诱导的KB细胞中,(+)CLA(5 μmol/L)使P-gp表达相对于溶媒对照上调了54.5%,并使Rh123蓄积减少了28.2%,而(-)CLA(5 μmol/L)使P-gp表达下调了15.9%,并使Rh123蓄积增加了18.0%。这些结果表明,(-)CLA可能是一种P-gp抑制剂,(+)CLA可能是一种调节剂,对P-gp活性具有浓度依赖性双相效应,当与其他P-gp底物药物合用时可能导致药物相互作用。